Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: HR+/HER2-negative Breast Cancer
Interventions: TOS-358, Fulvestrant, Palbociclib, Ribociclib; Drug
Lead sponsor: Totus Medicines; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more

Conditions: Major Depressive Disorder, Mood Disorders
Interventions: Rumination-Focused CBT, Relaxation-based Therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 14 Years to 17 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 3
States / cities: Columbus, Ohio • Salt Lake City, Utah

Conditions: Intracranial Pressure Increase
Interventions: Video ophthalmoscope; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 4 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autism
Interventions: Pathways and Resources for Engagement and Participation (PREP); Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 13 Years to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
Interventions: ImPart - Improving Chronic Kidney Disease Decisional Partnerships; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Gut -Microbiota, Inflammation Biomarkers, Pain Assessment, Joint Pain
Interventions: Wild blueberry, Placebo; Dietary Supplement
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 40 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy
Interventions: Mangafodipir, Gadolinium; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
Interventions: oxaliplatin, capecitabine, Keytruda, CDX-1140; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Esophageal Lesion, Barrett Esophagus, Gastrointestinal Lesions
Interventions: Endoscopic Submucosal Dissection; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy with MEKi-EGFRi, combination therapy with MEKi.; Other · Drug
Lead sponsor: Mandana Kamgar, MD; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cirrhosis, Liver
Interventions: Leucine enriched essential amino acid (EEA/LEU), Balanced amino acid supplement (BAA); Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Suicide, Mental Health Issue
Interventions: Analog Devices Inc.; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 144 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cervical Spondylosis With Myelopathy, Cervical Radiculopathy, Cervical Disc Herniation, Degenerative Disc Disease
Interventions: Cervical arthroplasty, Semi-Constrained Nuvasive Simplify, Unconstrained Biomet Zimmer Mobi-C; Procedure · Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiovascular Risk Factor
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 77,000 participants
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Neuromuscular Blocks
Interventions: 2 mg/kg sugammadex, 0.07 mg/kg neostigmine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Edentulous Mouth, Periodontal Diseases, Periodontitis, Adult, Microbial Colonization
Interventions: Microbial Sampling; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Postural Tachycardia Syndrome
Interventions: pyridostigmine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 15 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Carcinoma
Interventions: Educational Intervention, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Davis, California • Duarte, California • Irvine, California + 13 more

Conditions: Cannabis
Interventions: CBD, THC; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Disc Herniation
Interventions: Discogen Low pulsed ultrasound treatment, Discogen Sham Treatment; Device
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Central Nervous System Neoplasm
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Posttraumatic Stress Disorder (PTSD), Substance Use Disorder (SUD)
Interventions: Trauma Informed Heart Rate Variability Biofeedback, Present Centered Therapy; Behavioral
Lead sponsor: Coatesville VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Coatesville, Pennsylvania

Conditions: Metastatic Colorectal Cancer
Interventions: Ivonescimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Mechanisms of Rumination Change in Adolescent Depression

Non-Invasive and Non-Contact Intracranial Pressure Waveform Recording Using Dynamic Video Ophthalmoscopy

The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver

A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)

Dietary Wild Blueberries and Joint Health

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Endoscopic Submucosal Dissection (ESD)

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Proximal Risk for Suicide in Adolescents

Comparison of Artificial Disc Implants in Cervical Disc Arthroplasty

Community Benefit of No-charge Calcium Score Screening Program

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

Changes in Microbial Status From Dentate, Edentulous and After Dental Implant Placement

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

The Pharmacokinetics of a Hemp-Based Topical Product

Discogen for Low Back Pain

Cerebrospinal Fluid Biomarkers for Brain Tumors

The Many Roads to Trauma Recovery: A Clinical Trial Comparing Empirically Supported Treatments for Veterans With Co-Morbid Posttraumatic Stress and Substance Use Disorder Symptoms

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer